Hirakawa B[au] - Search Results

Year	Number of Results
2001	1
2004	1
2005	1
2008	1
2010	1
2011	2
2012	1
2013	1
2014	3
2018	1
2019	1
2020	1
2022	1
2024	0

1

Reversible lysine-targeted probes reveal residence time-based kinase selectivity.

Yang T, Cuesta A, Wan X, Craven GB, Hirakawa B, Khamphavong P, May JR, Kath JC, Lapek JD Jr, Niessen S, Burlingame AL, Carelli JD, Taunton J. Yang T, et al. Among authors: hirakawa b. Nat Chem Biol. 2022 Sep;18(9):934-941. doi: 10.1038/s41589-022-01019-1. Epub 2022 May 19. Nat Chem Biol. 2022. PMID: 35590003 Free PMC article.

2

Phenotypic Characterization of Targeted Knockdown of Cyclin-Dependent Kinases in the Intestinal Epithelial Cells.

Lu S, Sung T, Amaro M, Hirakawa B, Jessen B, Hu W. Lu S, et al. Among authors: hirakawa b. Toxicol Sci. 2020 Sep 1;177(1):226-234. doi: 10.1093/toxsci/kfaa092. Toxicol Sci. 2020. PMID: 32556214

3

Intestinal Toxicity in Rats Following Administration of CDK4/6 Inhibitors Is Independent of Primary Pharmacology.

Thibault S, Hu W, Hirakawa B, Kalabat D, Franks T, Sung T, Khoh-Reiter S, Lu S, Finkelstein M, Jessen B, Sacaan A. Thibault S, et al. Among authors: hirakawa b. Mol Cancer Ther. 2019 Feb;18(2):257-266. doi: 10.1158/1535-7163.MCT-18-0734. Epub 2018 Nov 6. Mol Cancer Ther. 2019. PMID: 30401694

4

Responses of the steroidogenic pathway from exposure to methyl-tert-butyl ether and tert-butanol.

de Peyster A, Mihaich E, Kim DH, Elyea WA, Nemec MJ, Hirakawa BP, Leggieri SE. de Peyster A, et al. Among authors: hirakawa bp. Toxicology. 2014 May 7;319:23-37. doi: 10.1016/j.tox.2014.01.015. Epub 2014 Feb 19. Toxicology. 2014. PMID: 24560773 Free article.

5

A tyrosine kinase inhibitor-induced myocardial degeneration in rats through off-target phosphodiesterase inhibition.

Hu W, Hirakawa B, Jessen B, Lee M, Aguirre S. Hu W, et al. Among authors: hirakawa b. J Appl Toxicol. 2012 Dec;32(12):1008-20. doi: 10.1002/jat.2801. Epub 2012 Aug 31. J Appl Toxicol. 2012. PMID: 22936366

6

miR-208a as a biomarker of isoproterenol-induced cardiac injury in Sod2+/- and C57BL/6J wild-type mice.

Liu L, Aguirre SA, Evering WE, Hirakawa BP, May JR, Palacio K, Wang J, Zhang Y, Stevens GJ. Liu L, et al. Among authors: hirakawa bp. Toxicol Pathol. 2014 Oct;42(7):1117-29. doi: 10.1177/0192623314525684. Epub 2014 Apr 8. Toxicol Pathol. 2014. PMID: 24713317

7

Pan-FGFR inhibition leads to blockade of FGF23 signaling, soft tissue mineralization, and cardiovascular dysfunction.

Yanochko GM, Vitsky A, Heyen JR, Hirakawa B, Lam JL, May J, Nichols T, Sace F, Trajkovic D, Blasi E. Yanochko GM, et al. Among authors: hirakawa b. Toxicol Sci. 2013 Oct;135(2):451-64. doi: 10.1093/toxsci/kft161. Epub 2013 Jul 20. Toxicol Sci. 2013. PMID: 23872713

8

Characterization of IDN-6556 (3-[2-(2-tert-butyl-phenylaminooxalyl)-amino]-propionylamino]-4-oxo-5-(2,3,5,6-tetrafluoro-phenoxy)-pentanoic acid): a liver-targeted caspase inhibitor.

Hoglen NC, Chen LS, Fisher CD, Hirakawa BP, Groessl T, Contreras PC. Hoglen NC, et al. Among authors: hirakawa bp. J Pharmacol Exp Ther. 2004 May;309(2):634-40. doi: 10.1124/jpet.103.062034. Epub 2004 Jan 23. J Pharmacol Exp Ther. 2004. PMID: 14742742

9

First-in-class pan caspase inhibitor developed for the treatment of liver disease.

Linton SD, Aja T, Armstrong RA, Bai X, Chen LS, Chen N, Ching B, Contreras P, Diaz JL, Fisher CD, Fritz LC, Gladstone P, Groessl T, Gu X, Herrmann J, Hirakawa BP, Hoglen NC, Jahangiri KG, Kalish VJ, Karanewsky DS, Kodandapani L, Krebs J, McQuiston J, Meduna SP, Nalley K, Robinson ED, Sayers RO, Sebring K, Spada AP, Ternansky RJ, Tomaselli KJ, Ullman BR, Valentino KL, Weeks S, Winn D, Wu JC, Yeo P, Zhang CZ. Linton SD, et al. Among authors: hirakawa bp. J Med Chem. 2005 Nov 3;48(22):6779-82. doi: 10.1021/jm050307e. J Med Chem. 2005. PMID: 16250635

10

Characterization of the caspase inhibitor IDN-1965 in a model of apoptosis-associated liver injury.

Hoglen NC, Hirakawa BP, Fisher CD, Weeks S, Srinivasan A, Wong AM, Valentino KL, Tomaselli KJ, Bai X, Karanewsky DS, Contreras PC. Hoglen NC, et al. Among authors: hirakawa bp. J Pharmacol Exp Ther. 2001 May;297(2):811-8. J Pharmacol Exp Ther. 2001. PMID: 11303074

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

14 results

Results by year

Search Page

Filters

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

Search Results

14 results

Results by year